Human Anti-TNFRSF12A Recombinant Antibody (clone TPP-2084) (CAT#: HPAB-0051-LSX)

Figure 1 Interaction of TWEAKR ectodomain with antibodies and reference antibodies.

Shown is the result of an ELISA with TWEAKR-Fc fusion protein (TPP-2202) coating (1 mg/ml) and 0.08 mg/ml (open bars) and 0.3 mg/ml (filled bars) of biotinylated IgG as soluble binding partner. Detection was done with Streptavidin-HRP and Amplex-Red substrate. Y is "ELISA signal intensity [Rfu]"; X are "antibody constructs tested": a is "TPP-2090"; b is "TPP-2084"; c is "PDL-192(TPP-1104)"; d is "P4A8(TPP-1324)"; e is "P3G5(TPP-2195)"; f is "136.1(TPP-2194)"; h is "ITEM1"; i is "ITEM4"; j is a murine isotype control; k is a human isotype control. All tested antibodies show saturated binding with a concentration of 80 ng/ml.

Figure 2 Interaction of TWEAKR cysteine rich domain with antibodies and reference antibodies.

Shown is the result of an ELISA with TWEAKR(34-68)-Fc fusion protein (TPP-2203) coating (1 mg/ml) and 0.08 mg/ml (open bars) and 0.3 mg/ml (filled bars) of biotinylated IgG as soluble binding partner. Detection was done with Streptavidin-HRP and Amplex-Red substrate. Y is "ELISA signal intensity [Rfu]"; X are "antibody constructs tested": a is "TPP-2090"; b is "TPP-2084"; c is "PDL-192(TPP-1104)"; d is "P4A8(TPP-1324)"; e is "P3G5(TPP-2195)"; f is "136.1(TPP-2194)"; h is "ITEM1"; i is "ITEM4"; j is a murine isotype control; k is a human isotype control. The antibodies bind to the cysteine rich domain.

Figure 3 Efficacy of anti-TWEAKR antibodies in the human renal cell cancer xenograft 786-O after treatment with 0.3, 1.0 and 3.0 mg/kg (i.v., q4dx3) started at day 7 after tumor cell inoculation.

Shown are final tumor weights at day 40. A is "Vehicle group, treated with PBS (i.v. q4dx3)". B is "Isotype, 3 mg/kg", C is "TPP-2084, 0.3 mg/kg", D is "TPP-2084, 1 mg/kg", E is "TPP-2084, 3 mg/kg", F is "TPP-2090, 0.3 mg/kg", G is "TPP-2090, 1 mg/kg", H is "TPP-2090, 3 mg/kg". (Y is "Tumor weights means of n=8; SD [g]").